RIGEL PHARMACEUTICALS INC Form 8-K April 01, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2009

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)


0-29889 (Commission File No.)

94-3248524 (IRS Employer Identification No.)

1180 Veterans Boulevard

South San Francisco, CA 94080

(Address of principal executive offices and zip code)



Item 5.02.	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangemen	ats of Certain Officers.

(e) On March 30, 2009, the Compensation Committee of the Board of Directors of Rigel Pharmaceuticals, Inc. approved the 2009 Cash Incentive Plan. The 2009 Cash Incentive Plan is attached as Exhibit 10.28 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

10.28 2009 Cash Incentive Plan.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RIGEL PHARMACEUTICALS, INC.

Dated: March 31, 2009

By: /s/ Dolly Vance

Dolly Vance

Senior Vice President, General Counsel and

Corporate Secretary

3

EXHIBIT INDEX

Exhibit No. 10.28 Description

2009 Cash Incentive Plan.